Marker beacon

EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Wednesday, April 10, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Monday, March 18, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Tuesday, April 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

Cannabis Genetics Company Phylos Announces Elite Seeds: High-Potency, Production-Ready F1 Hybrid Seeds for Controlled Environments

Retrieved on: 
Tuesday, April 2, 2024
F1, Genetics, Candy, Genome, Seed, Plant, Inbreeding, Cannabis, Research and development, Cheese, Marker beacon, Economics, Agriculture

PORTLAND, Ore., April 2, 2024 /PRNewswire/ -- Cannabis genetics company Phylos® has added 10 Elite varieties to its growing menu of proprietary F1 hybrid seeds. Phylos Elites produce uniform plants that outperform clones and improve the economics of commercial indoor and controlled-environment operations.

Key Points: 
  • Elite cannabis seeds produce uniform genetics that outperform clones with higher yields, lower production costs, stress tolerance, and HLVd-resistance
    PORTLAND, Ore., April 2, 2024 /PRNewswire/ -- Cannabis genetics company Phylos® has added 10 Elite varieties to its growing menu of proprietary F1 hybrid seeds.
  • "Elite seeds generate vigorous plants that produce premium, standardized consumer products while reducing notoriously high costs of operating indoor and greenhouse grows," noted Ralph Risch, Phylos CEO.
  • "To our knowledge, Elites are the first seeds bred and validated to perform in high-stress, rapid cycle time, controlled environments."
  • Phylos F1 hybrid Elite seeds can be easily trialed in the same room as clones for cultivators to quickly see how seeds are the future of large-scale, cost-efficient cannabis production.

First Skeleton-Wide Study of Blood Cell Formation Yields Surprising Findings

Retrieved on: 
Wednesday, March 20, 2024
Humerus, Cell, Bone marrow, Infection, Disease, Bleeding, Laser, Mechanics, Anatomy, Mouse, Research, Nature, Experimental Hematology, Doctor of Philosophy, Femur, Human, Sternum, Arteriole, Neutrophil, Blood, G-CSF, Division, Marker beacon, Tibia, Skull, Skeleton, Ageing, Vaccine

CINCINNATI, March 20, 2024 /PRNewswire/ -- Imagine being able to count the different types of blood cells being formed inside the tiny bones of a mouse and pinpointing the strings and clusters of cells within the bone marrow that are responsible for producing specific types of blood cells.

Key Points: 
  • "Meanwhile, efforts to stimulate production of certain blood cell types may be dramatically improved by focusing on specific bone types."
  • The key discoveries reported in the paper include:
    New tools allowing visualization of blood production inside the bone, allowing defining the basic anatomy of blood cell formation.
  • Among several examples: blood loss triggered rapid red blood cell production in the sternum, tibia, vertebrae, and humerus -- but not in the skull.
  • Importantly, the process developed for this study allowed the team to analyze blood cell development in multiple parts of the skeleton.

Boundary Stone Partners Announces Emily Domenech as Senior Vice President

Retrieved on: 
Tuesday, March 12, 2024
Marker beacon, Talent, Committee, Transport, Bachelor, Commerce, BSP, Fiscal, Policy, Towson University, Presidency of Donald Trump, Acqui-hiring, Bully pulpit, Talent management, Environmental science, International, Eckerd College, Climate, National Society, PHR, Community organizing, Culture, FACS, Foreign policy, Master, Associate, White, Georgetown University, NEPA, Knowledge, University, Rural development, Senior, House, Human, Client, Public affairs, SHRM, Marymount University, Government, Natural Resources, George Mason University, EPA, BPI, Management

WASHINGTON, March 12, 2024 /PRNewswire/ -- Today, Boundary Stone Partners (BSP) announced Emily Domenech will join the team as a Senior Vice President, bringing her years of experience serving House Republican leadership on Capitol Hill to benefit the firm's clients. BSP continues to grow, hiring experts across the energy ecosystem as the industry booms.

Key Points: 
  • WASHINGTON, March 12, 2024 /PRNewswire/ -- Today, Boundary Stone Partners (BSP) announced Emily Domenech will join the team as a Senior Vice President, bringing her years of experience serving House Republican leadership on Capitol Hill to benefit the firm's clients.
  • Domenech joins BSP from the Office of Speaker Mike Johnson, where she held the position of Senior Policy Advisor to the Speaker of the House.
  • "We are excited to welcome Emily's expertise and perspective at Boundary Stone Partners."
  • In addition to Domenech, the following individuals have also joined the Boundary Stone ranks:
    Dane Bahnsen , Director - Bahnsen has joined BSP's D.C. office as a Director supporting client teams.

Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

Retrieved on: 
Monday, February 19, 2024
Fast Track, EMA, Biotechnology, Scleroderma, FDA, Food, Treatment, Marker beacon, Therapy, GPCR, Patient, Acceleration, Fibrosis, Clinical trial, Disease, NDA, Pharmaceutical industry

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.

Key Points: 
  • MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.
  • [4]
    Professor Darren Kelly, Certa Therapeutics CEO and founder said, “We are thrilled to have received Fast Track Designation which supports further acceleration of the FT011 clinical development program.
  • Certa is progressing preparations toward a pivotal clinical trial of FT011 as a treatment for scleroderma.
  • C Denton, W Stevens, N Kruger, M Papadimitriou, F Khong, M Bradney, D Kelly, R Lafyatis “FT011 for the Treatment of Systemic Sclerosis.

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

Retrieved on: 
Thursday, February 15, 2024
Technology, Oncology, Defense, Genetics, Artificial Intelligence, Men, Clinical Trials, Other Technology, Science, Biotechnology, Veterans, Consumer, Other Science, Health, Research, HPC, Sonneborn–Berger score, University, Artificial intelligence, GRS, Database, Marker beacon, Risk, Argonne National Laboratory, Single-nucleotide polymorphism, MVP, Prostate cancer, Veteran, Disease, DOE, DNA

A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.

Key Points: 
  • A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.
  • Prostate cancer is the most frequently diagnosed non-skin cancer globally, and as such, it is a problem that affects the entire human population.
  • To understand the likelihood of an individual or population developing prostate cancer, researchers create what is known as a Genetic Risk Score (GRS).
  • This work was centered around a desire to understand the genetic makeup that increases risks for diseases like prostate cancer.

Infectious Disease Diagnostics for Influenza, RSV and SARS-CoV-2, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 14, 2024
MPH, RSV, Disease, Safety, Infection, Machine learning, SARS-CoV-2, Doctor of Philosophy, MRIGlobal, Research, Marker beacon, Vaccine

TORONTO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- The need for rapid, accessible and portable infectious disease diagnostics for seasonal respiratory diseases like influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 is critical to saving lives. Join an informative webinar focused on in vitro diagnostic development to meet this need, ranging from assay design, the use of bioinformatics in identifying emerging pathogens and optimizing assays, and securing the necessary regulatory approvals that support market access.

Key Points: 
  • In this free webinar, learn about the importance of expertise at all stages of infectious disease diagnostics development.
  • The featured speakers will discuss the value of bioinformatics in the development of infectious disease diagnostics.
  • TORONTO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- The need for rapid, accessible and portable infectious disease diagnostics for seasonal respiratory diseases like influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 is critical to saving lives.
  • Register for this webinar to learn how to effectively take an infectious disease diagnostic assay from initial design stages through regulatory approvals that support market access.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Genetics, Health, Agilent Technologies, BGI Group, Genetic disorder, Magnis, Illumina, Inc., DSM-IV codes, Genetic variation, Liquid biopsy, QIAGEN, Genomics, NGS, Marker beacon, Thermo Fisher Scientific, BGI, Fertilisation, Noninvasive prenatal testing, Genome, Informatics, CTC, Research, DNA, Medical device

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.